Ninety Percent Reduction in Cancer Mortality
After Chelation Therapy with EDTA
By Waiter Blumer, MD & Elmer M. Cranton, MD

ABSTRACT: Mortality from cancer was reduced 90% during an IS-year follow-up of 59 patients treated with calcium-EDTA. Only one of 59 treated patients (1.7%) died of cancer while 30 of 172 non-treated control subjects (17.6%) died of cancer (P = 0.002). Death from atherosclerosis was also reduced. Treated patients had no evidence of cancer at the time of entry into the study. Observations relate only to long term prevention of death from malignant disease, if chelation therapy is begun before clinical evidence of cancer occurs. Controls and treated patients lived in the same neighborhood, adjacent to a heavily traveled highway in a small Swiss city. Both groups were exposed to the same amount of lead from automobile exhaust, industrial pollution and other carcinogens. Exposure to carcinogens was no greater for the studied population than exists in most other metropolitan areas throughout the world. Statistical analysis showed EDTA chelation therapy to be the only significant difference between controls and treated patients to explain the marked reduction in cancer mortality.

EDTA is well recognized as a therapy for lead toxicity. EDTA also removes other toxic heavy metals and nutritional elements such as iron which promote cancer by catalyzing free radical pathology.

Lead from automobile exhausts, petrochemicals from wear of automobile tires, cadmium, and other carcinogens are present in higher concentrations adjacent to heavily traveled automobile highways. These substances cause cancer and potentiate other carcinogens.

It was reported in an earlier paper that cancer mortality among 231 adults living along a heavily traveled highway was higher than among persons living in a traffic-free section of the same city. Nervous disorders, headaches, fatigue, gastrointestinal disorders, depression, and substance abuse was also observed with higher frequency. It was postulated that lead exposure from automobile exhausts might be one cause of this difference.

Beginning in 1961, a group of 59 patients with such symptoms was treated with parenteral doses of calcium EDTA. Symptoms improved and urinary delta-amino levulinic acid diminished.

Subsequent to the EDTA chelation therapy, a decrease in cancer mortality was observed. When compared with a control group of untreated patients who did not receive EDTA, many fewer cancer deaths were recorded. The control group was similar to the treated group in all ways except for EDTA chelation therapy.

The purpose of this present study is to determine more precisely and to statistically analyze the long-term change in cancer mortality after treatment with EDTA.